Trial Profile
Prospective study of Rituximab for chronic graft vs host disease (GVHD) sub-optimally responsive to immunosuppressive therapy: Assessment of response.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 25 Jun 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 18 Jun 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason: Subject to verification.
- 23 Jun 2016 New trial record